Spoiler warning: Below there will be information about today's New York Times Strands puzzle.

Greetings! We’re losing Mercury from our early morning skies, but Venus and Saturn will appear quite close together this week ...

Your eyes will be drawn here to Rigel (Beta Orionis) and Betelgeuse (Alpha Orionis), two of the brightest stars in the sky. One of the most beautiful constellations in the sky is the celestial ...

Rigel's partner Kissei Pharmaceutical Co., Ltd. (Kissei) announced in January that the Korean Ministry of Food and Drug Safety approved TAVALISSE for the treatment of thrombocytopenia in adult ...

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago.

As an analyst tracking small-cap biotech names, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has always been one of my favorites, thanks to the company’s evolution from a TAVALISSE-centric company ...

GAVRETO net product sales were $9.0 million. GAVRETO became commercially available from Rigel in June 2024. REZLIDHIA net product sales were $6.1 million, growth of 25% compared to $4.9 million in ...